Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease

Next Previous
Search
Trial Profile

A 76-Week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a Statin in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anacetrapib (Primary)
  • Indications Coronary artery disease; Hyperlipidaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms DEFINE
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 18 Nov 2019 Results (n=332) assessing how haptoglobin CNV status impacts the effect of Anacetrapib on Impaired cholesterol efflux in diabetic patients were presented at the American Heart Association Scientific Sessions 2019
    • 01 Jun 2016 This trial is prematurely ended in Austria and Finland (End date: 31 Mar 2016).
    • 16 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Nov 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top